[
    {
        "name": "Abrysvo™",
        "vaccineId": 1,
        "pathogenId": 1, 
        "manufacturers": [
            {"manufacturerId": 1}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/168889/download?attachment" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "type": "Maternal",
                    "date": "08/2023",
                    "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
                },
                {
                    "name": "FDA",
                    "type": "Older Adults",
                    "date": "05/2023",
                    "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
                },
                {
                    "name": "EMA",
                    "type": "Maternal",
                    "date": "08/2023",
                    "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
                },
                {
                    "name": "EMA",
                    "type": "Older Adults",
                    "date": "08/2023",
                    "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
                }
        ],
        "approvalDate": "2023",
        "description": "Abrysvo™ is a vaccine developed by Pfizer to prevent Respiratory Syncytial Virus (RSV) infection. RSV is a common respiratory virus that usually causes mild, cold-like symptoms. It can be serious, especially for infants and older adults. Abrysvo™ is aimed at providing protection against RSV and is approved for use in various countries.",
        "link": "https://www.pfizer.com/products/product-detail/abrysvotm",
        "lastUpdated": "2024-AUG"
    },
    {
        "name": "Penbraya™",
        "vaccineId": 3,
        "pathogenId": 3, 
        "manufacturers": [
            {"manufacturerId": 1}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/151707/download?attachment" },
            { "licenserId": 2, "link": "https://catalogues.ema.europa.eu/node/3979/methodological-aspects" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "date": "20/10/2023",
                    "source": "https://www.fda.gov/vaccines-blood-biologics/vaccines/penbraya"
                }
        ],
        "description": "Penbraya™ is a pneumococcal vaccine developed by Pfizer. It is designed to protect against diseases caused by the bacterium Streptococcus pneumoniae, which can lead to conditions such as pneumonia, meningitis, and sepsis.",
        "link": "https://www.pfizer.com/products/product-detail/penbrayatm",
        "packageInsertLink": "https://www.fda.gov/media/173223/download?attachment",
        "lastUpdated": "TBU"
    },
    {
        "name": "Pfizer-BioNTech COVID-19 Vaccine",
        "vaccineId": 4,
        "pathogenId": 2, 
        "manufacturers": [
            { "manufacturerId": 5 },
            { "manufacturerId": 1 }
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty" },
            { "licenserId": 3, "link": "https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "date": "11/12/2020",
                    "source": "https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19"
                },
                {
                    "name": "EMA",
                    "date": "21/12/2020",
                    "source": "https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu"
                },
                {
                    "name": "FDA",
                    "date": "23/08/2023",
                    "source": "https://www.fda.gov/vaccines-blood-biologics/comirnaty"
                }
        ],
        "description": "The Pfizer-BioNTech COVID-19 Vaccine is an mRNA-based vaccine developed to prevent COVID-19, a disease caused by the SARS-CoV-2 virus. It works by instructing cells to produce a protein similar to the one found on the surface of the virus, which helps the immune system recognize and fight the virus if exposed. The vaccine has been widely distributed and is authorized for emergency use or fully approved in various countries.",
        "link": "https://www.pfizer.com/products/product-detail/pfizer-biontech-covid-19-vaccine",
        "vaccineType": "mRNA Covid vaccine",
        "comments": "First license, 12/2020",
        "revenue": "$11,220 million",
        "revenueLink": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf",
        "lastUpdated": "2023"
    },
    {
        "name": "Prevnar 13",
        "vaccineId": 5,
        "pathogenId": 3, 
        "manufacturers": [
            {"manufacturerId": 1}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/107657/download?attachment" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/documents/overview/prevenar-13-epar-summary-public_en.pdf" },
            { "licenserId": 3, "link": "https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/pneumonia" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "type": "Adults",
                    "date": "12/07/2016",
                    "source": "https://www.drugs.com/newdrugs/pfizer-receives-fda-approval-prevnar-13-adults-age-18-through-49-4409.html"
                },
                {
                    "name": "FDA",
                    "type": "Children (Aged 6-17)",
                    "date": "25/01/2023",
                    "source": "https://www.drugs.com/newdrugs/pfizer-receives-fda-approval-prevnar-13-vaccine-naive-children-adolescents-aged-6-years-through-17-3662.html"
                },
                {
                    "name": "FDA",
                    "type": "Older Adults (Aged 50 and Older)",
                    "date": "03/01/2012",
                    "source": "https://www.drugs.com/newdrugs/fda-expands-prevnar-13-vaccine-ages-50-older-3011.html"
                },
                {
                    "name": "FDA",
                    "type": "Children (6 weeks to 5 years)",
                    "date": "24/02/2010",
                    "source": "https://www.drugs.com/newdrugs/fda-expands-prevnar-13-vaccine-ages-50-older-3011.html"
                }
        ],
        "description": "Prevnar 13 is a pneumococcal conjugate vaccine developed by Pfizer to protect against pneumococcal disease caused by 13 types of Streptococcus pneumoniae bacteria. This vaccine is intended for use in children and adults to prevent infections such as pneumonia, meningitis, and bloodstream infections. It is widely used in various countries and is recommended for individuals at higher risk of pneumococcal disease.",
        "vaccineType": "13-valent pneumococcal conjugate vaccine",
        "link": "https://www.pfizer.com/products/product-detail/prevnar_13",
        "lastUpdated": "TBU"
    },
    {
        "name": "Prevnar 20™",
        "vaccineId": 6,
        "pathogenId": 3,
        "manufacturers": [
            {"manufacturerId": 1}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/151502/download?attachment" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20-previously-apexxnar" },
            { "licenserId": 3, "link": "https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/pneumococcal-vaccine-rates-information-sheet.pdf" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "date": "10/06/2021",
                    "source": "https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20"
                }
        ],
        "description": "Prevnar 20™ is a pneumococcal conjugate vaccine developed by Pfizer to protect against pneumococcal disease caused by 20 types of Streptococcus pneumoniae bacteria. This vaccine is intended for use in both children and adults to prevent severe infections such as pneumonia, meningitis, and bloodstream infections. Prevnar 20™ provides broader coverage than previous pneumococcal vaccines.",
        "link": "https://www.pfizer.com/products/product-detail/prevnar-20tm",
        "packageInsertLink": "https://fda.report/media/149987/Package+Insert+-+PREVNAR+20.pdf",
        "lastUpdated": "TBU"
    },
    {
        "name": "TicoVac™ (Tick-Borne Encephalitis Vaccine)",
        "vaccineId": 7,
        "pathogenId": 4,
        "manufacturers": [
            {"manufacturerId": 1}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/151502/download" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "date": "08/2021",
                    "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
                }
        ],
        "description": "TicoVac™ is a vaccine developed by Pfizer for the prevention of tick-borne encephalitis (TBE), a viral infection transmitted by ticks. TicoVac™ is designed to provide protection against TBE and is used in regions where the disease is endemic.",
        "vaccineType": "Tick-borne-encephalitis (TBE) whole-virus vaccine.",
        "link": "https://www.pfizer.com/products/product-detail/ticovac",
        "lastUpdated": "TBU"
    },
    {
        "name": "Trumenba™",
        "vaccineId": 8,
        "pathogenId": 5,
        "manufacturers": [
            {"manufacturerId": 1, "link": "https://www.fda.gov/media/89936/download"}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/vaccines-blood-biologics/vaccines/trumenba" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/trumenba" }
        ],
        "licensingDates": [
                {
                    "name": "FDA",
                    "date": "13/03/2017",
                    "source": "https://www.fda.gov/vaccines-blood-biologics/vaccines/trumenba"
                }
        ],
        "description": "Trumenba™ is a vaccine developed by Pfizer to protect against serogroup B of Neisseria meningitidis, a bacterium that causes meningococcal disease. Trumenba™ is designed to prevent invasive meningococcal B infections in adolescents and young adults.",
        "vaccineType": "Meningococcal B vaccine",
        "link": "https://www.pfizer.com/products/product-detail/trumenba",
        "lastUpdated": "TBU"
    },
    {
        "name": "Janssen COVID-19 Vaccine",
        "vaccineId": 9,
        "pathogenId": 2,
        "manufacturers": [
            {"manufacturerId": 2}
        ],
        "licensers": [
            { "licenserId": 1 },
            { "licenserId": 2 },
            { "licenserId": 3 }
        ],
        "description": "The Janssen COVID-19 Vaccine is a single-dose vaccine developed by Johnson & Johnson to protect against COVID-19. It is based on adenovirus technology and has been widely used for its convenience and effectiveness.",
        "link": "https://www.jnj.com/coronavirus/covid-19-vaccine",
        "lastUpdated": "TBU"
    },
    {
        "name": "Vaxzevria",
        "vaccineId": 10,
        "pathogenId": 2,
        "manufacturers": [
            {"manufacturerId": 6}
        ],
        "licensers": [
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca" },
            { "licenserId": 3, "link": "https://extranet.who.int/prequal/vaccines/vaxzevria" }
        ],
        "description": "Vaxzevria is a COVID-19 vaccine developed by AstraZeneca. It uses a viral vector platform to stimulate an immune response against the SARS-CoV-2 virus. The vaccine has been used globally to combat the COVID-19 pandemic.",
        "link": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-announces-covid-19-vaccine-update.html",
        "lastUpdated": "TBU"
    },
    {
        "name": "Gardasil",
        "vaccineId": 11,
        "pathogenId": 6,
        "manufacturers": [
            {"manufacturerId": 4}
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---Gardasil.pdf" },
            { "licenserId": 2, "link": "https://www.ema.europa.eu/en/documents/product-information/gardasil-epar-product-information_en.pdf" },
            { "licenserId": 3, "link": "https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV)" },
            { "licenserId": 4, "link": "https://assets.publishing.service.gov.uk/media/62291db38fa8f526d907f6c7/UKHSA-12304-HPV-healthcare-professional-factsheet.pdf"}
        ],
        "description": "Gardasil is a vaccine developed by Merck & Co., Inc. to protect against human papillomavirus (HPV) infection. It provides protection against the most common HPV types that cause cervical cancer, other genital cancers, and genital warts.",
        "link": "https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf",
        "lastUpdated": "TBU"
    },
    {
        "name": "FSME-Immun®",
        "vaccineId": 12,
        "pathogenId": 4,
        "manufacturers": [
            { "manufacturerId": 1 }
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/media/151994/download" }
        ],
        "description": "Pfizer’s TBE vaccine, marketed under the brand names FSME-Immun® and TicoVac™ in Europe, and TICOVAC™ in the U.S., is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. It is a vaccine developed by Pfizer for the prevention of tick-borne encephalitis (TBE), a viral infection transmitted by ticks. It is designed to provide protection against TBE and is used in regions where the disease is endemic.",
        "vaccineType": "Tick-borne-encephalitis (TBE) whole-virus vaccine.",
        "link": "https://www.pfizer.com/products/product-detail/ticovac",
        "lastUpdated": "TBU"
    },
    {
        "name": "Valneva VLA1553 Chikungunya Vaccine",
        "vaccineId": 13,
        "manufacturers": [
        ],
        "licensers": [
            { "licenserId": 1, "link": "https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-IXCHIQ.pdf" }
        ],
        "introduction": {
            "General Information": {
                "Map Vaccine Preventable Diseases": "Map by disease",
                "Vaccine SmPCs (FDA, EMA, WHO, others)": "Search by disease, include combos",
                "Product profiles": "",
                "Pipeline products - summary table": "By click, TPP",
                "Failed products": ""  
            },
            "Company products, pipeline": {
                "VPD-BoD, Product presentations, Monograph": "",
                "Pivotal publications / data vaccines": "",
                "Interviews": "Advertorial",
                "Relevant literature": "",
                "Pipeline products - detailed information (TPP)": ""
            }
        },
        "productProfile": [
            {
                "type": "ema",
                "name": "Short Target Product Profile Phase 3:<br/>Valnea VLA1533 - Chikungunya vaccine (fast track)",
                "composition": "Monovalent live-attuned <br/>(CHIKV-LR2006-OPY1; deleted nsPr3 (replicase complex))",
                "strainCoverage": "All strains",
                "indication": "'Adults and children'-P3:>18 years in endemic regions",
                "dosing": "Single dose i.m.",
                "immunogenicity": "Descriptive only (100% responders after 1 dose)",
                "efficacyEndpointsPhase3": "Immunogenicity (NT vs. surrogate) day 28",
                "efficacyData": "Surrogate 'protective titer'",
                "durationOfProtection": "Unknown, possibly lifelong",
                "coAdministration": "None",
                "reactogenicity": "Target? Similar to TdaP or other?",
                "safety": "N=4,000 US adults",
                "vaccinationGoal": "Individual protection",
                "others": "Fast track and Breakthrough Designation (FDA), PRIME (EMA)"
            },
            {
                "type": "fda",
                "name": "FDA-Product Profile: MVA-BN (JYNNEOS®) (MAH: Bavarian Nordic A/S)<br/>Suspension for injection; smallpox and monkeypox vaccine (Live attenuated, non-replicating)",
                "composition": "1 dose (0.5mL) contains modified vaccinia Ankara-Bavarian Nordic live virus (0.5x10% to 3.95x10 Inf.U); produced in chick embryo cells; storage: freezer, -20°C /refrigerator; shelf life: up to 3 yrs. at -20°C±10°C, 4 weeks at 2-8°C.",
                "strainCoverage": "Smallpox and monkeypox viruses.",
                "indication": "Active immunization against smallpox and mpox in adults ≥ 18 years at high risk of infection. To be used based on official recommendations.",
                "dosing": "2 doses (0.5ml each); 4-week interval; S.C.<br/>Booster: limited data available, if necessary single dose in healthy adults and 2 doses in immunocompromised patients (0, >28day).",
                "contraindication": "Hypersensitivity (administered if benefits > risk); limited data in pregnancy; no data in breastfeeding (administered if benefits > risk).",
                "immunogenicity": "Immunogenicity was assessed by ELISA and PRNT; percentage of seroresponders: 2 doses, 4wks. Interval, in Vaccinia-naive individuals, 42 days f/u, 77.2-99.8%; 2 doses, 4 wks. Interval, in Vaccinia-naive individuals, 42 days f/u, 77.2-99.8%; 2 doses, 4 wks. Interval, in vaccinia-experienced individuals, 42 days f/u, 85.5-100%.",
                "efficacyEndpointsPhase3": "Challenge study in NHP: 80-100% reduction in mortality; VEy based on immunogenicity and animal challenge studies.",
                "efficacyData": "VEs not included in the label:\nVEs against mpox (Epic study): 1 dose, 35.8% (95% CI, 22.1; 47.1); 2 doses, 66.0% (95%CI,47.4; 78.1).\nVEs against mpox (Multijurisdictional study): 1 dose, 75.2% (95% CI, 61.2; 84.2); 2 doses, 85.9% (95% CI, 73.8; 92.4).\nVEs against mpox (New York state study): 1 dose, 68% (95% CI,25; 87), 2 doses, 89% (95% CI,44; 98).",
                "durationOfProtection": "Unknown.",
                "coAdministration": "No data on the concomitant use with other vaccines.",
                "reactogenicity": "Vaccine-naive healthy adults: injection site pain (84.9%), redness (60.8%), swelling (51.6%), induration (45.4%), and itching (43.1%), muscle pain (42.8%), headache (34.8%), fatigue(30.4%), nausea (17.3%) and chills (10.4%); healthy adults previously vaccinated with smallpox vaccine: injection site redness (80.9%), pain (79.5%), induration (70.4%), swelling (67.2%), and itching (32.0%), fatigue (33.5%), headache (27.6%), and muscle pain (21.5%); similar reactogenicity in HIV-infected patients and adults with atopic dermatitis.",
                "safety": "Higher frequency of injection site erythma and swelling, headache, myalgia, chills, nausea, and fatigue in atopic dermatitis patients; May cause flare-ups or worsening skin condition in atopic dermatitis patients.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No safety/efficacy/effectiveness data in <18 yrs. and ≥ 65 yrs.; lower immune response in HIV-infected individuals; no data in other immunosuppressed individuals; dose intervals of less than 28 days should be avoided in immunosuppressed individuals.; authorization under exceptional circumstances; vial temperature should be 8-25°C before use."
            }
        ]
    }
]